Aurinia Pharmaceuticals Inc. cash flow to debt ratio of 181.33% indicates that the company generates enough cash to cover a substantial portion of its debt. This level indicates very strong financial health.

Aurinia Pharmaceuticals Inc.'s free cash flow has increased 206.99% from $44.11M last year to $135.41M, signaling increasing performance

Aurinia Pharmaceuticals Inc.'s debt to equity ratio is 0.10, which means that the company's assets are healthy financed, signaling financial stability.

Aurinia Pharmaceuticals Inc.'s debt has decreased relative to shareholder equity from 0.21 last year to 0.10 today, signaling strengthened financials

Aurinia Pharmaceuticals Inc. has a net cash position, so leverage is healthy.

Aurinia Pharmaceuticals Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Aurinia Pharmaceuticals Inc.'s profit margin has increased (4.02K%) in the last year from 2.45% to 100.84%, signaling increasing performance

Aurinia Pharmaceuticals Inc.'s short-term assets of $491.97M exceed its short-term liabilities of $93.72M

Aurinia Pharmaceuticals Inc.'s return on assets of 39.65% is higher than the 5.00% threshold, indicating efficient asset utilization

Aurinia Pharmaceuticals Inc.'s return on equity of 59.00%, is higher than 15.00%, indicating good performance

Aurinia Pharmaceuticals Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Aurinia Pharmaceuticals Inc. had positive net income in only 2 out of 5 years, indicating unstable earnings

Aurinia Pharmaceuticals Inc. has positive free cash flow, indicating the company generates cash after capital expenditures

Aurinia Pharmaceuticals Inc. has a free cash flow yield of 6.81%, which is above the 2.00% threshold, indicating strong cash generation relative to market value

Aurinia Pharmaceuticals Inc.'s yearly earnings has increased 4.89K% since last year from $5.75M to $287.20M, signaling increasing performance

Aurinia Pharmaceuticals Inc.'s yearly revenue has increased 20.38% since last year from $235.13M to $283.06M, signaling increasing performance

ROIC 21.27% (Source: FMP key-metrics). At or above the 10% threshold. Score: 2 of 2. The company is generating returns above the upper end of the typical US weighted-average cost of capital range under this definition of invested capital.

Aurinia Pharmaceuticals Inc.'s 3-year revenue CAGR of 28.30% is positive, indicating growing revenue over the past 3 years

Aurinia Pharmaceuticals Inc. had revenue growth in 4 out of 5 years, indicating consistent revenue performance

Aurinia Pharmaceuticals Inc. had positive ROE in only 2 out of 5 years, indicating inconsistent returns on equity

Aurinia Pharmaceuticals Inc. has insufficient data to evaluate this check.

Aurinia Pharmaceuticals Inc. has an earnings yield of 15.63%, which is above the 4.00% threshold, indicating the stock offers reasonable value relative to its earnings

Aurinia Pharmaceuticals Inc. is overvalued relative to its fair value price of 6.77 based on EBITDA multiple model

Aurinia Pharmaceuticals Inc. has an EV/EBITDA ratio of 13.02x, which is below the 20.00x threshold, indicating reasonable valuation relative to its operating earnings

Aurinia Pharmaceuticals Inc. is overvalued relative to its fair value price of -20.64 based on Earnings Fair Value model

Aurinia Pharmaceuticals Inc. had non-positive diluted EPS five years ago; the PEG ratio is not meaningful and the check fails.

Aurinia Pharmaceuticals Inc. has a price-to-book ratio of 3.27x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Aurinia Pharmaceuticals Inc. has a price-to-sales ratio of 6.45x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue